FMP
Y-mAbs Therapeutics, Inc.
YMAB
NASDAQ
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
4.83 USD
0.48 (9.94%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2025-03-04
26.5M
-0.15
-0.13
15.38%
2024-11-08
18.46M
-0.16
-0.14
14.29%
2024-08-12
22.8M
-0.21
-0.13
61.54%
2024-05-07
19.93M
-0.15
-0.12
25.00%
2024-02-29
23.36M
-0.02
-0.19
-89.47%
2023-11-13
20.45M
-0.18
-0.16
12.50%
2023-08-10
20.75M
-0.14
-0.24
-41.67%
2023-05-08
20.25M
-0.15
-0.31
-51.61%
2023-03-30
31.45M
0.03
-0.46
-106.52%
2022-11-07
12.54M
-0.63
-0.75
-16.00%
2022-08-08
10.8M
-0.94
-0.68
38.24%
2022-05-09
10.49M
-0.64
-0.71
-9.86%
2022-02-24
9.6M
-0.85
-0.71
19.72%
2021-11-04
8.96M
-0.66
-0.6
10.00%
2021-08-05
10.95M
-0.53
-0.68
-22.06%
2021-05-06
5.38M
0.75
0.61
22.95%
2021-02-25
20.75M
-0.49
-0.85
-42.35%
2020-11-05
0
-0.82
-0.8
2.50%
2020-08-06
0
-1.01
-0.69
46.38%
2020-05-07
0
-0.66
-0.63
4.76%
2020-03-12
0
-0.6
-0.67
-10.45%
2019-11-13
0
-0.7
-0.54
29.63%
2019-08-14
0
-0.53
-0.48
10.42%
2019-05-10
0
-0.47
-0.4
17.50%
2019-03-22
0
-0.42
-0.38
10.53%
2018-11-13
0
-0.42
-0.36
16.67%
2018-09-24
0
-0.22
0
-
2018-06-30
0
-0.32
0
-
2017-12-31
0
-0.28
0
-
2017-09-30
0
-0.11
0
-
2017-06-30
0
-0.17
0
-
2017-03-31
0
-0.17
0
-
